Aldophosphamides

Details Aldophosphamides Aldophosphamides

1986-06-30

1989-06-20

Sutto, Anton H.

Package making

C07F 940

Patent

active

048410853

ABSTRACT:
A compound having the structure ##STR1## wherein R is CH.sub.3 or C.sub.2 H.sub.5 1; R.sup.1 is NH.sub.2, NHCH.sub.3, NHC.sub.2 H.sub.5, NHC.sub.2 H.sub.4 Cl, N(CH.sub.3).sub.2, N(C.sub.2 H.sub.5).sub.2, N(C.sub.2 H.sub.4 Cl).sub.2, OCH.sub.3, C.sub.2 H.sub.5, CH.sub.3, or C.sub.2 H.sub.5, and R.sup.2 is N(C.sub.2 H.sub.4 Cl).sub.2 or NH C.sub.2 H.sub.4 Cl.
These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting the bone marrow with a solution comprising levels of said compound sufficient to eliminate occult leukemic clonogenic cells. Analogously tumor cells in a host or organ of a host may be eliminated by treatment of the host or host's organ with a compound of this description.
Compounds of this description are stable aldophosphamide analogs activatable by the action of an esterase and a subsequent E-2 elimination reaction to form acrolein and a phosphoramidic mustard of the formula: ##STR2## wherein R is NH.sub.2, NHCH.sub.3, NHC.sub.2 H.sub.5, NHC.sub.2 H.sub.4 Cl, N(CH.sub.3).sub.2, N(C.sub.2 H.sub.5, N(C.sub.2 H.sub.4 Cl).sub.2, OCH.sub.3, OC.sub.2 H.sub.5, CH.sub.3 or C.sub.2 H.sub.5.

REFERENCES:
patent: 2535173 (1950-12-01), Tawney
Sladek (1973), Can Res., 33:1150.
Conners et al., (1974), Biochemical Pharmacol., 23:115.
Cox et al., (1975), Cancer Res., 35:3755.
Friedman et al., (1979), Adv. Cancer Chemother., 1:143.
Sharkis et al., (1980), Blood, 55:521.
Korbling et al., (1982), Brit. J. Haematol., 52:89.
Hilton et al., (1984), Proc. Amer. Assoc. Cancer Res.
Hilton, (1984), Biochem. Pharmacol., 33:1867.
Hilton, (1984), Cancer Res., 44:5156.
Sladek et al., (1985), Cancer Res., 45:1549.
Stewart et al., (1985), Exp. Hematol, 13:267.
Struck et al., (1975), Heyden and Son, Ltd.
Norpoth, (1976), Cancer Treatment Reports, 60:437.
Peter et al., (1976), Cancer Treatment Reports, 60:429.
Struck, (1976), Cancer Treatment Reports, 60:317.
Frei et al., (1977), Cancer Treatment Reports, 61:1209.
Farquhar et al., (1979), J. of Labelled Compounds and Radiopharmaceuticals, XVI:615.
Farquhar et al., (1980), J. Labelled Compounds and Radiopharmaceuticals, XVII:159.
Zon et al., (1982), J. Pharm.Sci., 71:443.
Farquhar et al., (1983), J. Med. Chem., 26:1153.
Farquhar et al., (1983), J. Pharmaceutical Sciences, 72:324.
Garattini, (1983), European J. of Drug Metabolism and Pharmacokinetics, 8:97.
Struck et al., (1983), Brit. J. Cancer, 47:015-026.
Kohn and Sladek, (1985), Biochem. Pharmacol., 34:3465.
Smith and Sladek, (1985), Biochem. Pharmacol., 34:3459.
Yeager et al., Jul. 17, 1986, The New England Journal of Medicine, vol. 315.
Kohn, (1987), Cancer Res., 47:3180.
Herve, (1984), Investigational New Drugs, 2:245.
Struck and Alberts, (1984), Cancer Treatment Reports, 68:765.
de Jong et al., (1985), Cancer Res., 45:4001.
Gordon et al., (1985), Leukemia Research, 9:1017.
Montgomery and Struck, (1976), Cancer Treatment Rep., 60:381.
Struck, (1974), Cancer Res., 34:2933.
Dialog Search of the Scientific and Patent Literature.

Affiliated with

Also associated with

Rating

Aldophosphamides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aldophosphamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aldophosphamides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-526475